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Value of digoxin in patients with heart failure:
new pieces to the puzzle
Dirk J. van Veldhuisen*, Michiel Rienstra, and Peter van der Meer
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
This article refers to “Effect of digoxin in patients with
heart failure and mid-range (borderline) left ventricular
ejection fraction” by A.H. Abdul-Rahim et al., published
in this issue on pages 1139–1145.
Heart failure (HF) remains a large medical problem with an unac-
ceptably high morbidity and mortality despite optimal medical and
device treatment.1 Digoxin is the oldest drug in cardiovascular
medicine, and in the most recent HF guidelines of the Euro-
pean Society of Cardiology (ESC) of 2016, it received a IIb-B
recommendation,1 i.e. it may be considered in HF patients with
reduced ejection fraction (HFrEF) who are in sinus rhythm, and still
symptomatic despite treatment with an angiotensin-converting
enzyme (ACE) inhibitor or an angiotensin receptor blocker
(ARB) or an angiotensin-receptor neprilysin inhibitor (ARNI), a
beta-blocker and a mineralocorticoid receptor antagonist (MRA),
to reduce the risk of hospitalization. This IIb-B recommendation is
much lower than the IA level digoxin still had in the 2001 American
College of Cardiology/American Heart Association (ACC/AHA)
guidelines,2 and along with this change, the use of digoxin has
gradually declined from more than 60% in a large European study
in the 1990s3 to less than 10% in a more recent trial in patients
with HF and sinus rhythm (data from COMMANDER HF4). The
use of digoxin has also declined in patients with atrial fibrillation
(AF) (and HF), and in the 2016 ESC HF guidelines, digoxin is only
recommended for the treatment of patients with HFrEF and AF to
slow a rapid ventricular rate.1 Interestingly, not a single randomized
clinical trial has ever been conducted in this AF population.
The recommendation for digoxin is based on one large trial
(Digitalis Investigation Group, DIG), published in 1997, that was
conducted in almost 8000 patients in sinus rhythm.5 Patients in
the DIG trial were on ACE inhibitors and diuretics, but not on
beta-blockers, and the use of digoxin led to a 28% reduction in
hospitalizations. Since its publication, a large number of subanalyses
of the DIG trial have been conducted, which demonstrated that
digoxin was more effective in more advanced HF,6 and in patients
who had lower serum digoxin levels.7,8
In the present issue of the Journal, McMurray’s group from
Glasgow report the results of another subanalysis of the DIG trial,
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. i.e. the effect of digoxin in HF patients with mid-range (borderline)
ejection fraction [HFmrEF, i.e. left ventricular ejection fraction
(LVEF) 40–49%].9 In the 2016 ESC HF guidelines,1 this group was
specifically mentioned because around 20% of all HF patients fall
into this category, and this population had become somewhat of a
grey area.10 Indeed, in some HF studies this group had even been
excluded. It appeared useful to formally identify this HF population
as a separate group, because they seemed to respond differently
to treatment than patients with LVEF ≥50%, and to stimulate
new research into underlying pathophysiology. In the present
study from Glasgow,9 the effect of digoxin was thus examined
in HF patients with LVEF <40% (n= 5874), in patients with LVEF
40–49% (n=1195), and in patients with LVEF ≥50% (n= 719). The
primary outcome was the composite of cardiovascular death and
HF hospitalization (i.e. time to first event), and in clinical terms,
patients with HFmrEF resembled patients with HFrEF more than
those with HF and preserved ejection fraction (HFpEF).9 Event
rates in HFmrEF, however, were more similar to those in HFpEF
than to those in HFrEF. Digoxin reduced the primary endpoint
in patients with LVEF <40% by 29% [hazard ratio (HR) 0.71, 95%
confidence interval (CI) 0.65–0.77], by 17% in patients with LVEF
40–49% (HR 0.83, 95% CI 0.66-1.05), and by 12% in patients with
LVEF ≥50% (HR 0.88, 95% CI 0.65–1.19). This effect was mainly
due to reduced HF hospitalizations, and this reduction was 20% in
patients with LVEF 40–49% (HR 0.80, 95% CI 0.63–1.03). In other
words, the effect of digoxin was in the same direction, albeit smaller
in patients with HFmrEF, as it was in patients with HFrEF, while the
event rate was clearly smaller and more similar to that observed
in patients with HFpEF.
How can we comment on the present study and what are the
potential implications?
First, digoxin was safe in HF across the whole spectrum of LVEF,
i.e. also in the group of patients with HFmrEF.
Second, digoxin caused a (non-significant) 17% reduction in the
primary endpoint, which was mainly due to a 20% (non-significant)
reduction in HF hospitalizations. The present analysis in patients
with HFmrEF was relatively small (n=1195), when time-to-first
event analysis is used, particularly in a long-term follow-up study
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such as the DIG trial (average follow-up 37months).1 Indeed,
in chronic diseases such as HF, which is characterized by repeat
HF hospitalizations, including all hospitalizations, and not just
the first, may provide a more complete picture of the effect
of the drug.11,12 In the EMPHASIS-HF study, this increased the
effect of the MRA eplerenone from a 37% (with time-to-first
event analysis) to a 47% reduction (with repeat hospitalizations
analysis) (both P< 0.001).11 In the CHARM-Preserved study, the
initial time-to-first event analysis showed only a borderline, not
statistically significant benefit of the ARB candesartan, but with
repeat hospitalizations analysis, a 25% reduction of the composite
endpoint of HF hospitalizations and cardiovascular death was
observed (P= 0.003). This was related to the fact that in the
latter analysis, 939 HF hospitalizations (547 on placebo vs. 392
on candesartan) could be taken into the analysis,12 as compared
to only 509 HF hospitalizations (279 vs. 230, respectively) in the
time-to-first event analysis, i.e. a large increase in power. Because
of this, an increasing number of trials, such as the Affirm-AHF
(NCT02937454) and PARAGON-HF study,13 are now using repeat
hospitalizations for their primary analysis. It would be interesting
to know what the effect of digoxin in the present study population
of HFmrEF patients (LVEF 40–49%) would have been if the repeat
hospitalizations would have been employed.
A third comment should be made about the digoxin dose. It has
been well known and documented that there is a strong associa-
tion between higher doses of digoxin and increased mortality,2,14
and this was shown not only in the DIG study,7,8 but also in earlier
studies with digoxin,15 and was reported again recently in the ARIS-
TOTLE trial.16 The general consensus is that serum digoxin con-
centrations ≥1.0 ng/mL should be avoided, and that dosing should
be aimed at reaching concentrations of 0.5–0.9 ng/mL. It would be
interesting to learn whether such an effect was also present in the
current subanalysis in patients with HFmrEF, and indeed, it cannot
be excluded that the findings could have been more favourable for
digoxin if lower doses of the drug would have been used.
Clearly, some comment should be made about the limitations
of the present study, and the authors have mostly acknowledged
this.9 This relates of course to the retrospective nature of the
study, its rather low power (with time-to-first event analysis), the
relatively high doses of digoxin used, and—very importantly—the
fact that 20–25 years ago, beta-blockers and MRAs (and ARNI)
and devices were not yet used. Particularly event rates will be
largely influenced by this, and of course, the effect of digoxin
against a background of these drugs is largely unknown.
Despite these points, the authors are to be congratulated with
the present data, since they provide a new piece to the puzzle
of whether or not digoxin should have a place in the treatment
of patients with HF, and if so, how, where and with which doses.
Indeed, this group from Glasgow has published some provocative
data on digoxin in HF before,17 and these reports are important
and useful, since they help to define the role of this very cheap
and potentially useful drug for these patients. Nevertheless, new
controlled data in contemporary HF patients with sinus rhythm
and with AF, who are treated according to current HF guidelines,1
are very much needed.
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